Balversa (erdafitinib)
Balversa is a kinase inhibitor used for the treatment of patients with locally advanced or metastatic bladder cancer (urothelial carcinoma) that has susceptible FGFR3 or FGFR2 genetic alteration (as determined by an FDA-approved test) and has progressed during or after platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.
Janssen offers 2 financial assistance programs for patients who have been prescribed Balversa:
Janssen CarePath Savings Program
With this program, eligible, privately insured patients will pay just $5 per month for Balversa, with an annual benefit up to $25,000. The savings may apply toward copay, coinsurance, or deductible, depending on the patient’s health insurance plan.
Johnson & Johnson Patient Assistance Foundation
This program provides Balversa free of charge to patients who meet certain financial criteria and who are uninsured, underinsured, or enrolled in Medicare Part D.
Bavencio (avelumab)
Bavencio is a PD-L1 inhibitor used for the treatment of patients with locally advanced or metastatic bladder cancer (urothelial carcinoma) whose disease progressed during or after platinum-containing chemotherapy, or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. Bavencio is also used as maintenance treatment of patients with locally advanced or metastatic bladder cancer that has not progressed with first-line platinum-containing chemotherapy.
EMD Serono offers 2 financial assistance programs for patients using Bavencio:
CoverOne Co-Pay Assistance Program
Through this program, patients with private insurance will be responsible for a $0 copay for Bavencio at participating medical facilities and pharmacies, and may be eligible for copay assistance up to a maximum of $30,000 annually.
CoverOne Patient Assistance Program
This program provides Bavencio at no charge for patients who meet certain income, insurance, and residency eligibility criteria.
Jelmyto (mitomycin)
Jelmyto is a first-in-class alkylating drug, a pyelocalyceal solution used for the treatment of adults with low-grade upper tract urothelial cancer.
UroGen Support offers 2 financial assistance programs for patients who have been prescribed Jelmyto:
UroGen Support Copay Program
Eligible patients who have commercial or private health insurance will pay as little as $50 per dose of Jelmyto, with a maximum benefit of $4,000 per dose, and a maximum total benefit of up to $13,000 per year. To qualify for this program, patients must be enrolled in the UroGen Support Program.
UroGen Support Patient Assistance Program
for an FDA-approved indication and have an adjusted gross income of up to 400% of the federal poverty level, may receive Jelmyto for free.
Keytruda (pembrolizumab)
Keytruda is a PD-1 inhibitor used for the treatment of patients with locally advanced or metastatic bladder cancer (urothelial carcinoma) who are not eligible for cisplatin-containing chemotherapy; and for patients whose disease has progressed during or after platinum-containing chemotherapy, or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy, regardless of PD-L1 status. Keytruda is also used for the treatment of patients with Bacillus Calmette-Gu rin unresponsive, high-risk, non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors, who are ineligible for or have elected not to undergo cystectomy.
Merck offers 2 financial assistance programs for patients using Keytruda:
Merck Co-pay Assistance Program
Privately insured patients will pay the first $25 of their copay per Keytruda infusion. The maximum benefit per calendar year is $25,000.
Merck Patient Assistance Program
Patients without insurance or prescription coverage may be eligible to receive Keytruda at no cost. Eligible patients must have a household income of $64,000 or less for individuals, $87,100 or less for a couple, or $132,000 or less for a family of 4. Patients with insurance, including Medicare Part D, who still have trouble paying for their medicines may request that an exception be made, provided their household income is not above a set limit.
Opdivo (nivolumab)
Opdivo is a PD-1 inhibitor used for the treatment of patients with locally advanced or metastatic bladder cancer (urothelial carcinoma) whose disease progressed during or after platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. Opdivo is also indicated for the adjuvant treatment of patients with bladder cancer who are at high risk of recurrence after undergoing radical resection (surgical removal) of the tumor.
Bristol Myers Squibb Access Support offers 2 financial assistance programs for patients using Opdivo:
BMS Oncology Co-Pay Assistance Program
This program provides financial assistance with out-of-pocket deductibles, copay, or coinsurance costs for eligible patients with private insurance who have been prescribed Opdivo. Patients pay a $25 copay, while BMS covers the remaining amount, up to $25,000 annually per medication.
Bristol Myers Squibb Patient Assistance Foundation
BMS Access Support can make a referral to independent charitable foundations, including BMS Patient Assistance Foundation. Patients who don’t have public or private insurance that helps to pay for Opdivo may be eligible for help paying for their prescription medication if they receive treatment as an outpatient and have an annual income of less than 300% of the federal poverty level, up to $38,640 for an individual or $52,260 for a family of 2.
Padcev (enfortumab vedotin-ejfv) Injection
Padcev is a Nectin-4-directed antibody and microtubule inhibitor conjugate used for the treatment of adults with locally advanced or metastatic bladder cancer (urothelial carcinoma) who have received a PD-1 or PD-L1 inhibitor, and a platinum-containing chemotherapy in the neoadjuvant or adjuvant, locally advanced or metastatic setting.
Astellas and Seagen offer 2 financial assistance programs for patients using Padcev:
Padcev Copay Assistance Program
Eligible patients who have private insurance pay as little as $5 per dose of Padcev, with a maximum program benefit of $25,000 annually.
Padcev Patient Assistance Program
Eligible patients who are uninsured or underinsured may receive their prescription of Padcev at no cost through this program.
Tecentriq (atezolizumab)
Tecentriq is a PD-L1 inhibitor used for the treatment of patients with locally advanced or metastatic bladder cancer (urothelial carcinoma) who are not eligible for cisplatin-containing chemotherapy and whose tumors express PD-L1, as determined by an FDA-approved test; and for patients who are not eligible for platinum-containing therapy, regardless of PD-L1 status.
Genentech Oncology offers 2 financial assistance programs for patients using Tecentriq:
Genentech Oncology Co-pay Assistance Program
Eligible patients with private insurance will pay just a $5 copay per prescription or infusion of Tecentriq, with an annual benefit limit of $25,000. Retroactive requests for assistance will be honored if the prescription was filled within 180 days before enrollment in this program.
Genentech Patient Foundation
This foundation provides Tecentriq free of charge to uninsured or underinsured patients whose annual household income is less than $150,000 and who meet specific financial criteria.
Trodelvy (sacituzumab govitecanhziy) Injection
Trodelvy is a Trop-2-directed antibody and topoisomerase inhibitor conjugate used for the treatment of adults with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a PD-1 or PD-L1 inhibitor.
Gilead, through Trodelvy Access Support, offers 2 financial assistance programs for patients using Trodelvy:
Trodelvy Savings Program
Eligible patients who have commercial or private insurance may pay $0 out-of-pocket for Trodelvy, with a maximum benefit of $25,000 per year.
Gilead Patient Assistance Program
Eligible patients who are uninsured or underinsured may receive Trodelvy at no cost.
Table. Drugs Prescribed for Bladder Cancer (Urothelial Carcinoma)
- Drug name (generic name)
- Drug company
- Indications
- Patient support services
- Balversa (erdafitinib)
- Janssen
- Treatment of locally advanced or metastatic bladder cancer that has a susceptible FGFR3 or FGFR2 genetic mutation and has progressed during or after chemotherapy
- Janssen CarePath Savings Program
877-227-3728
Johnson & Johnson Patient Assistance Foundation
800-652-6227
- Bavencio (avelumab)
- EMD Serono
- Treatment of locally
advanced
or metastatic
bladder
cancer that
progressed during or
after platinum-based
chemotherapy
or within 12
months of neoadjuvant or
adjuvant platinum-based
chemotherapy
Maintenance treatment of locally advanced or metastatic bladder cancer that has not progressed with first-line platinumcontaining chemotherapy - CoverOne Co-Pay Assistance Program
844-826-8371
CoverOne Patient Assistance Program
844-826-8371
- Jelmyto (mitomycin)
- UroGen Pharma
- Treatment of adults with low-grade upper tract urothelial cancer
- UroGen Support Copay Program
855-535-6986
UroGen Support Patient Assistance Program
855-535-6986
- Keytruda (pembrolizumab)
- Merck
- Treatment of patients
with locally advanced or
metastatic
bladder cancer
who are not eligible for
platinum-containing
therapy and whose
tumors express PD-
L1, as
determined by an FDAapproved
test
Treatment of patients with locally advanced or metastatic urothelial carcinoma whose disease progressed during or after platinum-based chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy
Treatment of patients with Bacillus Calmette-Gu rin unresponsive, high-risk, non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors, who are ineligible for or have elected not to undergo cystectomy - Merck Co-pay Assistance Program
855-257-3932
Merck Patient Assistance Program
800-727-5400
- Opdivo (nivolumab)
- Bristol Myers Squibb
- Treatment of locally
advanced or metastatic
bladder cancer (urothelial
carcinoma) that progressed
during or after platinum-based
chemotherapy
or within 12 months
of neoadjuvant or
adjuvant platinum-based
chemotherapy
Adjuvant treatment of patients with bladder cancer who are at high risk of recurrence after undergoing radical resection (surgical removal) of the tumor - BMS Oncology Co-Pay Assistance Program
800-861-0048
Bristol Myers Squibb Patient Assistance Foundation
800-736-0003
- Padcev (enfortumab vedotin-ejfv) Injection
- Astellas/Seagen
- Treatment of locally advanced or metastatic bladder (urothelial) cancer after treatment with a PD-1 or PD-L1 inhibitor, and a platinum-containing chemotherapy in the neoadjuvant or adjuvant, locally advanced or metastatic setting
- Padcev Copay Assistance Program
888-472-3238
Padcev Patient Assistance Program
888-472-3238
- Tecentriq (atezolizumab)
- Genentech
- Treatment of locally
advanced or metastatic
bladder cancer in patients
who are not eligible for
cisplatin-containing therapy,
and whose tumors express
PD-L1, as determined by an
FDA-approved
tes
Treatment of patients who are not eligible for any platinum-containing chemotherapy, regardless of PD-L1 status - Genentech Oncology Co-pay Assistance Program
855-692-6729
Genentech Patient Foundation
888-941-3331
- Trodelvy (sacituzumab govitecan-hziy) Injection
- Gilead
- Treatment of adults with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a PD-1 or PD-L1 inhibitor
- Trodelvy Savings Program
844-876-3358
Gilead Patient Assistance Program
844-876-3358